NCT07096999 SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
| NCT ID | NCT07096999 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan Rogel Cancer Center |
| Condition | Metastatic Castration-Resistant Prostate Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-23 |
| Primary Completion | 2031-01-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-01-23 with a primary completion date of 2031-01-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Eligibility Criteria
Inclusion Criteria: * \* 177Lu-617 PSMA treatment scheduled for mCRPC * Clinically stable as determined by the nuclear medicine clinicians * Male * ≥ 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Contact & Investigator
Yuni K Dewaraja
PRINCIPAL INVESTIGATOR
University of Michigan Rogel Cancer Center
Frequently Asked Questions
Who can join the NCT07096999 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Castration-Resistant Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07096999 currently recruiting?
Yes, NCT07096999 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Michigan Rogel Cancer Center to inquire about joining.
Where is the NCT07096999 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07096999 clinical trial?
NCT07096999 is sponsored by University of Michigan Rogel Cancer Center. The principal investigator is Yuni K Dewaraja at University of Michigan Rogel Cancer Center. The trial plans to enroll 60 participants.